Clinigen Group opens Global Operations Centre
Will improve distribution and stock levels
Peter George, chief executive of Clinigen, said: ‘We are continuing to expand and have ambitious plans for the future. It is essential that we have the right resource and facilities to service our clients, both now, and as we continue to develop.’
The firm says the new 8,000ft2 warehousing and distribution facilities will enable it to stock and distribute pharmaceutical products to its global customer base in a fast and efficient manner.
The new Operations Centre combined with the company's headquarters in Burton, have created more than 30 new jobs in recent months. In total the firm employs 300 staff.
Clinigen Group was formed in 2010 by the merger of three companies: Clinigen CTS (formerly Keats Healthcare) and Clinigen GAP, which make up Clinigen's services division, and Clinigen Healthcare, the Group's products business.
The Group operates across the clinical lifecycle of a drug, from Phase 1 clinical trials to the end of patent and beyond.
You may also like
Distribution
![Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally]()
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally
Read moreClinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Trending Articles
You may also like
Distribution
![Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally]()
Santhera and Clinigen partner to distribute DMD treatment AGAMREE to eligible patients globally
Clinigen Group will be respsonsible for the distribution of Duchenne muscular dystrophy (DMD) treatment AGAMREE (vamorolone) in regions not currently covered by Santhera or its distribution partners
Regulatory
![NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development]()
NSF Pharma Biotech Conference Q&A highlights priorities for contamination control, quality culture and workforce development
The discussion underscored the growing importance of aligning employee behaviours with compliance objectives, while also addressing the industry’s ongoing challenges around regulatory benchmarking and operational consistency
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Neuland Laboratories announces new $20m process development lab in Hyderabad]()
Neuland Laboratories announces new $20m process development lab in Hyderabad
The new facility will be fully operational by October 2026 and will give clients earlier manufacturability insight when looking to scale up, through the incorporation of non-GMP kilo labs as well as AI-driven route scouting, parallel synthesis and ELNs